The efficacy of Femal in women with premenstrual syndrome: a randomised, double-blind, parallel-group, placebo-controlled, multicentre study

被引:16
|
作者
Gerhardsen, Gerhard [1 ]
Hansen, Anne V. [2 ]
Killi, Marianne [3 ]
Fornitz, Gitte Gleerup [4 ]
Pedersen, Frank [5 ]
Roos, Signe Barfod [6 ,7 ]
机构
[1] Greverud Legesenter, Oppegard 1415, Norway
[2] Univ Copenhagen, Fac Life Sci, Copenhagen, Denmark
[3] Fartein Valens Vej 45, Kolbotn, Norway
[4] Amager Hosp, Med Ctr, Copenhagen, Denmark
[5] Herning Hosp, Herning, Denmark
[6] Kommune Hosp Copenhagen, Dept Clin Biochem, Gentofte, Denmark
[7] Univ Copenhagen, Hellerup, Denmark
关键词
herbal medicinal product; pollen; premenstrual syndrome; sleep disturbance;
D O I
10.1007/s12325-008-0072-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Introduction: A double-blind, placebo-controlled, randomised, parallel-group, multicentre study was conducted to evaluate the effect of a pollen-based herbal medicinal product, Femal (R) (Sea-Band Ltd, Leicestershire, UK), on premenstrual sleep disturbances (PSD) in women with premenstrual syndrome (PMS). Methods: Femal, 160 mg twice-daily, was given for four menstrual cycles to 50 women, and placebo to 51 women. PSD were evaluated on a visual analogue scale prior to and after the four cycles. The effect on overall PMS symptoms was assessed with the Steiner premenstrual tension syndrome (PMTS) self-rating questionnaire. The results were analysed statistically based on intention to treat. Results: Femal treatment resulted in a significant reduction in PSD (P < 0.05) whereas placebo had no significant effect (P > 0.05). In a subgroup analysis of women with irritability as their main PMS symptom cluster, the reduction of PSD was even more pronounced (P < 0.001). There was no significant difference in overall degree of PMS symptom reduction between Femal and placebo when all participating women were evaluated (P > 0.05). However, in women with irritability as their main PMS symptom cluster, Femal treatment resulted in a significant reduction of the Steiner score (P < 0.05). The frequency of adverse events was not significantly different in women on Femal compared to women on placebo (P > 0.05). No serious adverse events were recorded. Conclusions: Femal treatment reduced PSD to a significant degree, particularly in women with irritability as their main PMS symptom. Femal treatment also reduced overall PMS symptoms in women with irritability (but not dysphoria) as their main PMS symptom. The safety of Femal and its efficacy in PSD and other symptoms in women with irritability as the main symptom cluster makes this herbal medicinal product a promising addition to the therapeutic arsenal for women with PMS.
引用
收藏
页码:595 / 607
页数:13
相关论文
共 50 条
  • [41] Effect of Peppermint Oil on Premenstrual Syndrome: A Randomized, Double-Blind Placebo-Controlled Study
    Delavar, Mouloud Agajani
    Ebrahimi, Soheila
    Esmaeilzadeh, Sedigheh
    Khamse, Azam
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2019, 21 (03)
  • [42] Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial
    Pasquale Caponnetto
    Davide Campagna
    Jasjit S. Ahluwalia
    Christopher Russell
    Marilena Maglia
    Paolo Marco Riela
    Carmelo Fabio Longo
    Barbara Busa
    Riccardo Polosa
    BMC Medicine, 21
  • [43] Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial
    Caponnetto, Pasquale
    Campagna, Davide
    Ahluwalia, Jasjit S.
    Russell, Christopher
    Maglia, Marilena
    Riela, Paolo Marco
    Longo, Carmelo Fabio
    Busa, Barbara
    Polosa, Riccardo
    BMC MEDICINE, 2023, 21 (01)
  • [44] EFFICACY AND SAFETY OF GLUCOLO PLUS IN TYPE 2 DIABETES MANAGEMENT (GLEEN STUDY): A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL.
    Zarruk, A.
    Zarruk, R.
    Pagnota, V.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A177 - A177
  • [45] Efficacy of systemic lidocaine in postoperative delirium in elderly patients undergoing laparoscopic colorectal surgery: study protocol for a multicentre, prospective, double-blind, randomised, parallel-group, superiority, placebo-controlled trial
    Liao, Xincheng
    Fu, Bingbing
    Yun, Jia
    Lin, Huifen
    Qian, Bin
    Yao, Yusheng
    BMJ OPEN, 2022, 12 (05): : e056959
  • [46] Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study
    Inoue, Yuichi
    Shimizu, Tetsuo
    Hirata, Koichi
    Uchimura, Naohisa
    Ishigooka, Jun
    Oka, Yasunori
    Ikeda, Junji
    Tomida, Takayuki
    Hattori, Nobutaka
    SLEEP MEDICINE, 2013, 14 (11) : 1085 - 1091
  • [47] The effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a double-blind active extension of the multicentre, randomised, double-blind, parallel-group placebo-controlled study
    Comi, G.
    Abramsky, O.
    Arbizu, T.
    Boiko, A.
    Gold, R.
    Havrdova, E.
    Komoly, S.
    Selmaj, K. W.
    Sharrack, B.
    Filippi, M.
    JOURNAL OF NEUROLOGY, 2008, 255 : 46 - 46
  • [48] Efficacy of Venlafaxine ER in patients with social anxiety disorder:: a double-blind, placebo-controlled, parallel-group comparison with paroxetine
    Allgulander, C
    Mangano, R
    Zhang, J
    Dahl, AA
    Lepola, U
    Sjödin, I
    Emilien, G
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2004, 19 (06) : 387 - 396
  • [49] A randomized, double-blind, parallel-group, placebo-controlled Phase 3 trial to evaluate efficacy and safety of ocrelizumab in PPMS
    Montalban, Xavier
    Hemmer, Bernhard
    Rammohan, Kottil W.
    Giovannoni, Gavin
    De Seze, Jerome
    Bar-Or, Amit
    Arnold, Douglas L.
    Sauter, Annette
    Masterman, Donna
    Fontoura, Paulo
    Chin, Peter
    Garren, Hideki
    Wolinsky, Jerry S.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 17 - 17
  • [50] GABAPENTIN AS ADD-ON THERAPY IN REFRACTORY PARTIAL EPILEPSY - A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY
    OOMMEN, K
    PENRY, J
    RIELA, A
    ROWAN, AJ
    ROSENBAUM, D
    SCHEAR, M
    SIVAK, M
    WIENER, J
    SAUERMANN, W
    WIBBERG, M
    SMITH, D
    KRAMER, R
    YERBY, M
    LESSER, R
    FISHER, R
    SANDERS, P
    NORTH, R
    HOMAN, R
    ALEXANDER, J
    SHELLENBERGER, MK
    WALLACE, J
    SACKELLARES, J
    AASVED, K
    HIRSCHORN, K
    OLSON, L
    LEPPIK, I
    RASK, C
    ROSENFELD, W
    FROMM, GH
    NAGEL, N
    DREIFUSS, F
    BERTRAM, E
    COOPER, G
    LEE, SI
    OJEMANN, L
    WILENSKY, A
    ABOUKHALIL, B
    COURVILLE, K
    MCLEAN, M
    RAMSAY, RE
    GUTERMAN, A
    MCJILTON, J
    SANCHEZ, R
    SLATER, J
    MATTSON, R
    SCHEYER, R
    TREIMAN, D
    HANDFORTH, A
    NEUROLOGY, 1993, 43 (11) : 2292 - 2298